• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » SSRIs vs SNRIs in Pediatric Anxiety Disorders: Which Are More Tolerable?

SSRIs vs SNRIs in Pediatric Anxiety Disorders: Which Are More Tolerable?

July 14, 2021
John Raiss, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Mills JA and Strawn JR, J Am Acad Child Adolesc Psychiatry 2020;59(11):1240–1251

STUDY Type: Meta-analysis

For children with anxiety disorders and OCD, SSRIs produce faster and greater improvement than SNRIs (Strawn JR et al, J Am Acad Child Adolesc Psychiatry 2018;57(4):235–244.e2). Unfortunately, adverse effects slow down our dose titration and increase the risk of treatment discontinuation, and we lack systematic evaluations of adverse effects in pediatric patients. How can we predict these effects?

The authors analyzed data on 2,631 children or adolescents from 18 prospective, randomized, placebo-controlled studies that evaluated the use of SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline) or SNRIs (atomoxetine, venlafaxine, duloxetine) in anxiety disorders in children and adolescents. Median duration of acute treatment was 11 weeks. Researchers calculated risk rates of abdominal pain, activation, diarrhea, nausea, insomnia, headache, sedation, discontinuation due to adverse effects, and suicidality. They also looked at disinhibition, increased motor activity, restlessness, fidgetiness, impulsivity, and irritability.

The authors found that SNRIs produced far fewer side effects than SSRIs. Only nausea was higher on SNRIs than on placebo, in contrast to SSRIs, which were associated with more abdominal pain, activation, headaches, and sedation. Adverse effect–related discontinuation was higher than placebo in SSRIs, and no different in SNRIs. Neither SSRIs nor SNRIs caused more treatment-emergent suicidality than placebo, although it is important to remember that this population was characterized by anxiety, not depression. It is also notable that of the 18 studies, 10 were federally funded and 8 were industry funded; however, there was no effort to compare them by category for such things as rates of suicidality.

CCPR’s Take
We are left with a conundrum. SSRIs are superior to SNRIs in efficacy and are the treatment of choice for anxiety, but they cause more side effects. If a patient develops activation, would the second choice be a different SSRI or an SNRI with less efficacy but less risk of activation? The authors suggest SNRIs might represent a good second choice, with some demonstrated efficacy in anxiety disorders and OCD and less activation risk. As a reminder, this is not true for depression, where we do not have proven efficacy of SNRIs in children and ­adolescents.
Child Psychiatry
KEYWORDS anxiety efficacy obsessive-compulsive-disorder ocd serotonin-norepinephine-reuptake-inhibitors serotonin-specific-reuptake-inhibitors side-effects snris ssris
John Raiss, MD.

ECT in Severe Adolescent Mood ­Disorders

More from this author
www.thecarlatreport.com
Issue Date: July 14, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Substance Use in Children and Adolescents, CCPR, July/August/September 2021
Teen Drinking: Risks and Responses
Addressing the Hazards of Performance-Enhancing Substances
Citalopram Plus Stimulants for Chronic Irritability?
SSRIs vs SNRIs in Pediatric Anxiety Disorders: Which Are More Tolerable?
Is It Time for an Online Tantrum Tool?
ADHD Prevalence in the US Black Population
Note From the Editor-in-Chief
Reading Research: Details Matter
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto29377983.jpg
    Child Psychiatry

    Anxiolytics in Children and Adolescents

    Learn about the pros and cons of the main categories of medications that clinicians typically use to treat anxiety in children and adolescents.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.